Direct Fed Microbial Market is Generating Revenue of $1.77 Billion by 2026, at CAGR 7.5% Growth Rate

Direct Fed Microbial

The demand for direct-fed microbial is on a rise, owing to surge in awareness toward improvement of animal health worldwide.

Rise in animal healthcare expenditure leads to easy availability of direct-fed microbial, which fuels the market growth”

— Mangesh Panhale

PORTLAND, OR, UNITED STATES, November 30, 2020 /EINPresswire.com/ — The global direct fed microbial market size was valued at $980 million in 2018, and is expected to reach $1,772 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

Direct-fed microbial contains live bacterial strains that help in the growth and development of animals. These beneficial organisms are replacing the use of antibiotics. However, due to the risk of development of antimicrobial-resistant organisms, the use of antibiotics as growth promoters for animal production has been banned. The administration of direct-fed microbial help to enhance the meat and milk production in animals such as cattle and poultry. In addition, these products modulate the immune response of animals and inhibit the growth of pathogenic organisms in the gastrointestinal tract of animals.

To Get the Sample Copy of Report Visit @ https://www.alliedmarketresearch.com/request-sample/6494

Increase in demand for meat & milk consumption and rise in profitability at same cost are the major factors driving the market growth of direct fed microbial market. Furthermore, significant surge in human population and increase in demand for protein content in the diet propel the market growth for direct-fed microbial. In addition, probiotics aid nutrient absorption by breaking down the complex compounds, which, in turn, helps to reduce the cost of animal production and increases the profitability of the animal producers. However, enforcement of stringent regulations regarding the vigorous usage of these microorganisms in animal diet and increase in cost of production are the major factors hampering thedirect fed microbial market growth. Conversely, ban on the usage of antibiotics in animal diet in the developed nations such the U.S., Germany, and the UK and rise in animal health concerns are anticipated to offer remunerative opportunities for market expansion in the near future.

The direct fed microbial report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.

By product, the lactobacillus segment accounted for 62% of the total direct fed microbial market share in 2018, and is expected to exhibit a prominent growth rate in the near future, owing to its increased usage in the livestock diet. Lactobacillus is the most widely used probiotics in the livestock diet, as it is considered safe and more beneficial as compared to the other bacterial species.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/6494

By livestock, the poultry segment dominated the direct fed microbial market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the fact that poultry is the most consumed animal meat across the globe. Furthermore, individuals prefer poultry other than other livestock animals.

By region, North America accounted for the major direct fed microbial market share in 2018 and is expected to continue this trend, owing to easy availability of direct fed microbial products. Moreover, surge in the demand for probiotics and rise in awareness towards maintenance of healthy lifestyle in the region are the major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of direct fed microbial.

The Major Key Players Are:

Koninklijke DSM N. V, Bio-Vet, Archer-Daniels-Midland Company, CHR. Hansen A/S, E. I. Du Pont De Nemours And Company, Novozymes A/S, Kemin Industries, Inc., BASF SE (BASF Corporation), Evonik Industries Ag, and Adisseo.

Access Full Report @ https://www.alliedmarketresearch.com/direct-fed-microbial-market-A06129

Similar Reports:

Anti-Counterfeit Packaging Market Analysis and Industry Forecast, 2027

mHealth Market Analysis and Industry Forecast, 2027

Syphilis Testing Market Analysis and Industry Forecast, 2027

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

K12 INC. INVESTORS WITH LOSSES GREATER THAN $100,000 ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C.

Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C.

Securities Investigation On Behalf Of Investors Of K12 Inc. Who Have Suffered Significant Losses

NEW YORK, USA, November 30, 2020 /EINPresswire.com/ — PHILADELPHIA, Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of K12 Inc. (“K12” or the “Company”) (NYSE: LRN) to determine whether the Company engaged in securities fraud or other unlawful business practices.

INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE SECURITIES OF K12 BETWEEN APRIL 27, 2020 AND SEPTEMBER 18, 2020, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $1000,000 ARE ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C., MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, MYARNOFF@KEHOELAWFIRM.COM, SECURITIES@KEHOELAWFIRM.COM, TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.

A class action lawsuit has been filed seeking to recover damages on behalf of K12 investors who purchased, or otherwise acquired, the securities of K12 during the Class Period and suffered losses.

According to the class action complaint, K12, allegedly, made false and misleading statements to the public throughout the Class Period and failed to disclose that (1) K12 lacked the technological capabilities, infrastructure, and expertise to support the increased demand for virtual and blended education necessitated by the global pandemic; (2) K12 lacked adequate cyberattack protocols and protections to prevent the disabling of its computer systems; (3) K12 was unable to provide the necessary levels of administrative support and training to teachers, students, and parents; (4) and K12’s officers lacked a reasonable basis for their positive statements about the Company’s business, operations, and prospects.

Kehoe Law Firm, P.C., with offices in New York and Philadelphia, is a multidisciplinary, plaintiff–side law firm dedicated to protecting investors from securities fraud, breaches of fiduciary duties, and corporate misconduct. Combined, the partners at Kehoe Law Firm have served as Lead Counsel or Co-Lead Counsel in cases that have recovered more than $10 billion on behalf of institutional and individual investors.

This press release may constitute attorney advertising.

Michael Yarnoff, Esq.
Kehoe Law Firm, P.C.
+12157926676
info@kehoelawfirm.com


Source: EIN Presswire

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Dr. Paul Elliott, Neurologist, Celebrates 19 Years of Distinguished Service with the Epilepsy Foundation of Florida

Neurologist, Dr. Paul Elliott is pleased to announce that he has devoted nearly two very productive decades of work at the Epilepsy Foundation of Florida

STUART, FL, UNITED STATES, November 30, 2020 /EINPresswire.com/ — Neurologist, Dr. Paul Elliott is pleased to announce that he has devoted nearly two very productive decades of work to aid the collective efforts of the medical and scientific professionals at the Epilepsy Foundation of Florida.

The Epilepsy Foundation of Florida is just one chapter in a national network of charitable organizations that provide services and programs for those who are dealing with epilepsy across the nation. These services include education on the science of epilepsy, its treatment, and ways an epileptic can better cope with this condition.

These services include a 24/7 help line, community forums, a children’s activity program, seizure education, the “My Seizure Diary” free self management tool advocacy, support for sudden unexpected death in epilepsy (SUDEP) support, a wellness institute, and research.
As a board certified Occupational and Neurological Medicine. Dr. Paul Elliott has been a valuable asset to the foundation in the areas of research, education, and advocacy.

Dr. Paul Elliott has worked closely with the experts at the Epilepsy Foundation of Florida to curate a robust research library and network that encompass the spectrum of discovery from concept to development. Dr. Paul Elliott has helped the Foundation to foster the development of new research professionals to support fresh avenues of discovery which will lead to better quality care and treatments.

In the area of advocacy, Dr. Paul Elliott has been invaluable with his in depth knowledge of neurobiology and occupational medicine. Because he has published and presented scientific studies in Neurological Medicine, occupational medicine, and Osteopathy, his advocacy has come with a depth and breadth of knowledge and authority which make his efforts eminently valuable.

Likewise, in the foundation’s educational efforts, Dr. Paul Elliott has been a great resource. While scientific knowledge of the brain is far from complete, Dr. Paul Elliott’s expertise and dedication to the cause have brought valuable insights to many people struggling with epilepsy, the friends and families of those living with epilepsy, those who directly care for someone living with the condition, and for many professionals who provide care and treatment for the condition.

Dr. Paul Elliott’s contributions in time and donations to the foundation have also been instrumental in the progress of the foundation’s Wellness Institute. This organization is dedicated to the prospect that those who live with epilepsy are entitled to the fullest and most productive life possible.

Today, Dr. Paul Elliott continues to provide Adult Neurological Consultation and Diagnostic Testing for patients dealing with a host of conditions and has been praised highly by both his peers and patients.

Caroline Hunter
Web Presence, LLC
+17862338220
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Biologics Industry To Recover From COVID-19 Crisis At 15% CAGR

Biologics Market Report 2020-30: COVID-19 Impact And Recovery

Biologics Global Market Report 2020-30: COVID-19 Impact And Recovery

The Business Research Company’s Biologics Market Report – Opportunities And Strategies – Global Forecast To 2030

LONDON, GREATER LONDON, UK, November 30, 2020 /EINPresswire.com/ — Avail up to 50% off on ALL research reports at: https://www.thebusinessresearchcompany.com/global-market-reports. Offer applies until Dec 31st.

Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease that have limited treatment options. According to a biologics market overview by TBRC, there has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab (Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.

The biologics market report covers sales of biologics and related services by entities that produce biologics to treat and prevent various microbial diseases and cancers. This industry includes establishments that produce products that are composed of sugars, proteins, nucleic acids, and a combination of all these substances isolated from humans, animal and microorganisms or produced from biotechnology methods.

Due to the worldwide supply and demand failures of drugs due to the COVID-19 outbreak, the global biologics market size is expected to decline from $269.2 billion in 2019 to $239.2 billion in 2020 at a compound annual growth rate (CAGR) of -11.2%. Biologic drug shortages because of an inadequate production of biologics is hampering the market growth. This inadequate or slowed production is due to the restrictions imposed by governments of various countries to shutdown factories or function with minimal staffing to contain the spread of virus and keep the staff safe. The market is then expected to recover and grow at a CAGR of 15% from 2021 and reach $464.7 billion in 2023.

Here Is A List Of Similar Reports By The Business Research Company:

Oral Biologics And Biosimilars Market – By Therapeutic Mechanism (Tumor Necrosis Factor-Alpha Inhibitors, Lymphocyte Modulators, Interleukin Inhibitors, GPCR (insulin, growth hormone, parathyroid hormone) Modulators, Immunostimulants, Others), By Disease (Diabetes, Arthritis & Chron`s Disease, Cancer, Infectious Diseases, Other Autoimmune Diseases, Others Diseases), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Pharmaceuticals Market – By Type (Pharmaceutical Drugs, Biologics), By Type Of Pharmaceutical Drugs (Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Musculoskeletal Disorder Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs), By Type Of Biologics Drugs (Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/pharmaceuticals-market

Pharmaceutical Drugs And Biologics Logistics Market – By Type (Cold-Chain Logistics And Non-Cold Chain Logistics), And By Region, Opportunities And Strategies – Global Forecast To 2021
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-and-biologics-logistics-market

Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

SVHI PRP Therapy Announces New Online Consult Option for PRP for Hair Loss in the Bay Area

PRP Therapy for Hair Loss for Bay Area

PRP for hair near me

SVHI PRP Therapy offers "platelet rich plasma" treatment for hair loss using industry-standard techniques.

Our online consultation makes the first encounter very easy for our potential clients.”

— Miguel Canales

SAN MATEO, CALIFORNIA, USA, November 30, 2020 /EINPresswire.com/ — SHVI PRP Therapy, a Bay Area clinic focused on treatments for PRP (Platelet Rich Plasma) hair loss therapy at https://svhi-prp.com/, is proud to announce a new online option for the initial consultation for any patient who is searching for PRP for hair loss near them. Many patients are using the "work at home" trend to upgrade their hair, including using PRP for hair loss. They often use the common search for "PRP therapy for hair loss near me" as they try to find a best-in-class PRP for hair loss clinic in the area near Foster City, San Mateo, and Burlingame, California.

"Our online consultation makes the first encounter very easy for our potential clients," explained Miguel Canales, surgeon, and founder of SVHI PRP therapy. "PRP is just one option for hair loss therapy, and by meeting with the client over the Internet we can discuss not just PRP for hair loss but other options including hair transplantation. It makes it easy to find the best step for a man or woman's hair loss mitigation strategy."

Bay Area residents can book an online or a face-to-face appointment to discuss PRP for hair loss at https://svhi-prp.com/contact/. In addition, those who want to learn more about PRP therapy can visit the robust information page at https://svhi-prp.com/faq/ which contains newly updated information for November, 2020.

Indeed, men or women who want to look their best should extend their efforts beyond their hair and look at skincare issues; yet another website at https://svaestheticderm.com/ touches on these issues. Regardless of whether the issue is hair or skin, Dr. Miguel Canales offers no obligation consultations in the online format, where he can work with a patient, whether male or female, to improve their appearance.

ABOUT SVHI PRP THERAPY

SVHI PRP Therapy (https://svhi-prp.com/) is a Bay Area company based in Foster City, California that offers PRP for hair loss to clients from San Francisco to San Mateo, Palo Alto to Redwood City, Redwood City to Burlingame and beyond. Clients who are suffering from hair loss and are seeking innovative therapy come to SVHI PRP Therapy to explore their options, including PRP therapy for hair loss. The company offers a no-obligation consultation on hair loss with Dr. Miguel Canales, a recognized specialist in the hair loss industry, including hair transplantation.

Jason McDonald
JM Internet Group
+1 415-655-1071
email us here


Source: EIN Presswire

Los Angeles' New Med Spa Dr. Refresh Launches In-Home Aesthetic, Cosmetic and Wellness Packages for Groups

Dr. Refresh Team

Dr. Refresh Team

Dr. Refresh In-Home Services

Dr. Refresh In-Home Services

Dr. Refresh In-Home Services

Dr. Refresh In-Home Services

**Give the Gift of Wellness for the Holidays**

LOS ANGELES , CALIFORNIA , UNITED STATES , November 30, 2020 /EINPresswire.com/ — Dr Refresh the newly opened Los Angeles wellness med spa which launched this past summer is expanding to offer in-home services for popular aesthetic, wellness and recovery treatments. Considered an essential business in the era of COVID, Dr. Refresh’s new on-call and at-home services will bring the spa to one’s home and will feature Dr. Refresh’s 30 wellness and recovery treatments, as well as cosmetic enhancements for planning one’s best self for the holidays. Also related to the holidays, the Dr. Refresh team will be expanding offerings to offer rapid antigen nasal swab testing conducted by a nurse. The tests are 93% accurate and will provide results in around three minutes for a greater piece of mind during the holiday season.

With wellness at the forefront of 2020, Dr. Refresh’s new in-home services will also include hostess packages aimed to take holiday hosting to a socially distanced next level. Some of Dr. Refresh’s most popular offerings have been made accessible for in-home treatments and include IV Vitamin Infusions, Acupuncture, Lymphatic Drainage, Facial Injections, Body Contouring (cellulite reduction), Cupping, Herbology, Body Massage, select cosmetic treatments and more.

Also just in time for the holidays, the Dr Refresh team has created The COVID Refresh treatment which will have you looking your best for the new year. The COVID Refresh features a Zoom-tech neck treatment (to have you looking your best at all angles on Zoom), cryoskin body sculpting (to take off that “COVID 15”) and Dr. Refresh’s premium IV vitamin drip services to give your immune system a much needed boost.

Individuals interested in giving the gift of wellness this holiday season can receive information at DoctorRefresh.com and via 323.834.1333. Black Friday deal packages are extended through the first week of December. Gift cards are also available – For Dr. Refresh gift cards customers will receive a $50 credit for every $200 spent.

*Dr. Refresh’s at-home services are limited to the Los Angeles area.

About Dr. Refresh:
Dr. Refresh is a collection of wellness centers that curate the best of wellness, aesthetics and recovery. With one’s health at the forefront, the Dr. Refresh team blends western and traditional Chinese medicine, as well as cosmetic enhancements in partnership with surgeon Dr. Edmund Fisher. With a wellness center in Los Angeles and additional planned in 2021 at the Resort World development in Las Vegas, Dr. Refresh facilities provide sought after treatments with highlights including Vitamin IV Drip Infusion Therapy, Acupuncture, Lymphatic Drainage, Facial Injections, Body Contouring (cellulite reduction), Cupping, Herbology, Body Massage, as well as additional sought after treatments.

Jason Wanamaker
Dr. Refresh
+1 310-923-6547
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

R3 Stem Cell International Now Offering Stem Cell and Exosome Therapy Promotion for Canada

Stem Cell Therapy in Canada

best stem cell company

Best Stem Cell Clinic Canada

The US and International leader in regenerative therapies, R3 Stem Cell, is now offering Canada a promotional special for stem cell and exosome therapies.

Patients from Canada receive quality stem cell biologics with high cell counts for extremely affordable pricing at R3 International, and now 50 billion exosomes for free!”

— David Greene, MD, MBA

SCOTTSDALE, ARIZONA, USA, November 30, 2020 /EINPresswire.com/ — The US and International leader in regenerative therapies, R3 Stem Cell, is now offering Canada a promotional special for stem cell and exosome therapies. This includes a free 50 billion exosome therapy for each procedure over 50 million stem cells.

The procedures have shown to be extremely helpful for many medical conditions, including orthopedic, autoimmune, neurologic, autism, organ failure and for anti aging as well. R3 International has special stem cell programs for those with autism, kidney failure, COPD, post-stroke, diabetes and more.

R3 Stem Cell’s Centers have performed over 15,000 procedures in the past eight years. In that time, no patients have experienced a significant adverse event, with patient satisfaction exceeding 85%.

Patients have been treated from all Canadian cities, big and small. This includes Montreal, Toronto, Vancouver, Ottawa, Quebec, Hamilton, and surrounding areas. The stem cell therapy for Canada includes anywhere between 30 million and 200 million stem cells, with the treatments being administered by highly skilled doctors either by injection, intravenous, intrathecal, intramuscular or lymphatic.

The cost of stem cell therapy in Canada starts at only $2950 for 30 million cells, with an extra $1000 for 50 million cells. Exosomes are stem cell byproducts that have shown to be exceptionally beneficial when used in conjunction with stem cell therapies. The stem cell treatments and exosome therapies are performed at multiple Centers in Mexico, including Cancun, Tijuana and Mexicali.

All ground transportation is included, with VIP escorts from the airport and hotel to the clinic for the procedures. Each patients has a Personal Concierge Representative to assist with travel logistics and any questions during the process. Each patient undergoes a free virtual consultation with one of R3’s expert stem cell doctors.

According to R3 CEO David Greene, MD, MBA, “We worked very hard to ensure patients receive quality stem cell biologics with high cell counts for extremely affordable pricing. Our Centers are part of hospitals, surgery centers or medical complexes in order to make sure the most contemporary resources are available.”

Currently, almost half of R3’s patient base internationally comes from referrals and repeat patients. "That really says a lot about how successful the stem cell procedures are for patients. The kids with autism, the patients with kidney or lung issues and those with diabetes are often so happy they send in their friends!" added Dr. Greene.

For those in Canada interested in stem cell therapy, call R3 today to set up a free phone consultation at +1 (888) 988-0515 or visit the website at https://r3stemcell.com/canada for more information.

David Greene, MD, MBA
R3 Stem Cell International
+1 888-988-0515
email us here


Source: EIN Presswire

Discover EBRAINS: A look inside Europe’s new platform for the brain

BRUSSELS, BELGIUM, November 30, 2020 /EINPresswire.com/ — The publication Discover EBRAINS introduces the powerful EBRAINS research infrastructure to the world. EBRAINS has been created by the EU-funded Human Brain Project, and offers an extensive portfolio of brain data, scientific services, digital tools and computing resources for researchers and industry. The paper discusses the transformative impact of EBRAINS for neuroscience, brain medicine, and brain-inspired innovation in Europe.

EBRAINS is an accelerator for European ambitions in multidisciplinary brain research, combining cutting-edge neuroscience, high-performance computing and artificial intelligence. It offers researchers an extensive range of brain data and a digital research environment that connects many of the most advanced European lab facilities, supercomputing centers, clinics and technology hubs in a unique integrated system.

“We are on the cusp of a new era in brain research – unprecedented technologies are put at the service of science, while innovators are taking more and more ideas from neuroscience”, says Pawel Swieboda, CEO of EBRAINS and Director General of the Human Brain Project. "Now we show prospective users what this new infrastructure is all about, the many ways to engage with us on further co-developing it, and how it can help them make their mark in these rapidly growing fields.”

Synergy between neuroscience and technology

Today, high speed computing is changing the game in tackling brain complexity, neurotechnologies are becoming one of the global megatrends in health, and AI-developers are again looking at the brain for inspiration.

“Europe took an early lead in these areas with the Human Brain Project, which sits exactly at the intersection of brain science and computing”, says Katrin Amunts, Scientific Research Director of the HBP. Over the last seven years, the HBP teams, spread across Europe, have built, tested and used the digitally connected research platforms of EBRAINS in a Co-Design approach.

As part of its transitioning into a sustainable infrastructure, EBRAINS has applied for inclusion into the European ESFRI Roadmap, seeking to become a permanent addition to the EU’s research landscape, thereby contributing to accelerate neuroscience applications in industry and medicine.

A look inside (www.ebrains.eu/discover)
EBRAINS’ ambition is to provide the scientific community with an open state-of-the-art cloud-based ecosystem that fosters collaborative brain science and paves the way to ground-breaking discovery.

It offers unique resources like the most comprehensive 3D-atlas of the human brain, a Medical Informatics Platform for hospitals, simulation engines like The Virtual Brain, a neurorobotics platform, and access to supercompers of the European FENIX-network, as well as neuromorphic computers, which are modelled after the brain. A range of tailor-made tools helps scientists find, analyse, distribute, visualize and integrate brain data for their research. All components are available through a single online access point at www.ebrains.eu, and can be linked according to the concrete needs of a project.

Coming up: The HBP Science Case
In January, the publication of the Human Brain Project’s “Science Case”, will follow, describing the interplay of different scientific disciplines with the novel Research Infrastructure, the Human Brain Project’s vision of merging neuroscience, computing & technology in Europe, and the current research foci of the project for its final phase until 2023.

Digital event series
The two back-to-back publications are connected to several digital events, which present both the elements of the infrastructure itself and the current breakthrough research paradigms it enables in the HBP.

Politico Event
Tuesday, December 1, 2020 – 5 – 6 PM CET
Online
European research and innovation beyond 2020
Presented by EBRAINS

https://www.politico.eu/event/european-research-and-innovation-beyond-2020/
This POLITICO event will bring together policymakers of the European Commission, scientific experts and industry leaders for a Panel discussion on the future of European research and innovation. EBRAINS CEO and HBP Director General Pawel Swieboda will deliver the opening remarks.

Brain Matters Webinar
Since October, a new webinar series presents the HBP’s research focus areas on a monthly basis. https://ebrains.eu/news/new-ebrains-webinar

The third edition on December 10 will focus on Neurotechnology with researchers Rainer Goebel, Steve Furber and Christopher Summerfield.

Watch recordings of the first two editons here:

EBRAINS – In Search of Breakthroughs in Science and Medicine
with Katrin Amunts, Simon Eickhoff and Viktor Jirsa
https://www.youtube.com/watch?v=UTg06IeLOaU

Networks for Consciousness & Medical Use Cases
with Mavi Sanchez-Vives, Marcello Massimini and Pieter Roelfsema
https://www.youtube.com/watch?v=siwe3ZWMmeI

HBP Science Case Webinar
To be announced

Peter Zekert
Human Brain Project
+49 2461 6196860
email us here


Source: EIN Presswire

Perrin Conferences’ Annual New York Asbestos Litigation Conference Returns This December

The 2020 New York Asbestos Litigation Conference will be held virtually on December 8, 2020.

We’re excited to host prominent plaintiff and defense attorneys, judges, in-house counsel, and insurance professionals at this annual conference.”

— Lynnsey Perrin, President & CEO of Perrin Conferences

WAYNE, PENNSYLVANIA, UNITED STATES, November 30, 2020 /EINPresswire.com/ — Perrin Conferences has announced its virtual 2020 New York Asbestos Litigation Conference to be held on December 8, 2020. This conference will once again bring together leading attorneys and industry professionals for noteworthy panels and key discussions focused on New York asbestos litigation.

This year’s New York focused agenda will feature updates and perspectives on the current issues and outlook for 2021 in New York metro and upstate New York, appellate and summary judgment decisions, an update on talc litigation, a panel offering the judicial perspective, trials during COVID-19 and ethical issues to consider, and much more.

“We’re excited to host prominent plaintiff and defense attorneys, judges, in-house counsel, and insurance professionals at this annual conference. While we will miss the live aspect of this conference, we are bringing the same high-caliber speakers and trending topics to our audience,” said Lynnsey Perrin, President & CEO of Perrin Conferences.

This year’s conferences chairs are:
• Jennifer Wilcox Darger, Esq. Darger Errante Yavitz & Blau
• Charles M. Ferguson, Esq. Weitz & Luxenberg P.C.
• Paul Slater, Esq., Senior Counsel General Electric Company, Fairfield, CT

Speakers at the conference include:
• Joseph W. Belluck, Esq., Belluck & Fox, L.L.P., New York, NY
• Jerome H. Block, Esq., Levy Konigsberg LLP, New York, NY
• Daniel P. Blouin, Esq., Simmons Hanly Conroy LLC, New York, NY
• Patti L. Burshtyn, Esq., Weitz & Luxenberg, P.C., New York, NY
• Bernadette W. Catalana, Esq., MG+M The Law Firm, New York, NY
• Casey Chamra, Esq., O'Toole Scrivo, LLC, Cedar Grove, NJ
• Kerryann M. Cook, Esq., The Cook Group, New York, NY
• Meagan E. Dean, Esq., McGivney Kluger Clark & Intoccia, P.C., New York, NY
• Stephanie A. DiVita, Esq., The Law Firm of Pascarella DiVita
• Seth A. Dymond, Esq., Belluck & Fox, L.L.P., New York, NY
• Brian Early, Esq., The Early Law Firm, L.L.C., New York, NY
• Jordan Fox, Esq., Belluck & Fox, L.L.P., New York, NY
• Alani Golanski, Esq., Director, Appellate Litigation Unit, Weitz & Luxenberg, P.C., New York, NY
• David J. Goodearl, Esq., Leader Berkon Colao & Silverstein LLP, New York, NY
• Suzanne M. Halbardier, Esq., Barry McTiernan & Moore LLC, New York, NY
• Robert I. Komitor, Esq., Levy Konigsberg LLP, New York, NY
• Danny R. Kraft, Jr., Esq., Weitz & Luxenberg P.C., New York, NY
• Jonathan B. Kromberg, Esq., Darger Errante Yavitz & Blau, New York, NY
• Bridget Longoria, Esq., Assistant Vice President, Resolute Management Inc., Philadelphia, PA
• Stephen Novakidis, Esq., Foley & Mansfield, New York, NY
• Shelley Rossoff Olsen, Esq., Special Master, NYCAL, New York, NY
• Michelle Potter, Vice President, KCIC, Washington, DC
• Judith A. Yavitz, Esq., Darger Errante Yavitz & Blau LLP, New York, NY

Participating Judges include:
• Honorable Lucy Billings, Supreme Court of the State of New York, New York, NY
• Honorable Margaret A. Chan, Supreme Court, Civil Branch, New York, NY
• Hon. Erin P. Gall, Oneida County Supreme Court, Utica, NY
• Honorable Gerald Lebovits, Supreme Court of the State of New York, New York, NY
• Honorable Verna L. Saunders, Supreme Court of the State of New York, New York, NY
• Honorable Adam Silvera, Asbestos Coordinating Judge, Supreme Court of the State of New York, New York, NY

The conference also offers Continuing Legal Education (CLE) Credit and CE Adjuster Credit for qualified candidates. CE Adjuster Credit is pending in Texas and Florida. Please contact Bethany Corio at bcorio@perrinconferences.com if you have any questions regarding accreditation.
For more details on registration, please contact Lynnsey Perrin at lperrin@perrinconferences.com or visit the Perrin Conferences website at www.perrinconferences.com.

About Perrin Conferences
The leading national provider of joint plaintiff/defendant litigation conferences, Perrin Conferences offers comprehensive and specialized continuing legal education both virtual and live in an atmosphere of learning, networking, and sharing. Bringing together preeminent national talent in specialty legal fields, Perrin Conferences ensures its conferences deliver innovative content, networking opportunities, and career development. Attendees gain insights that cannot be found anywhere else. Follow the latest news from Perrin Conferences on LinkedIn at https://www.linkedin.com/company/perrin-conferences-llc or Twitter @PerrinConf. For more information on the company and upcoming conferences please visit www.perrinconferences.com.

Contact:
Amy Williams
Perrin Conferences
908-612-3586
awilliams@perrinconferences.com

Amy Williams
Perrin Conferences
+1 9086123586
email us here


Source: EIN Presswire

Digital Therapeutics Market 2020 Global Key Players, Size, Trends, Applications and Opportunities – Analysis to 2026

Global Digital Therapeutics Market Size 2020

Wiseguyreports.Com Publish New Market Research Report On-“Digital Therapeutics Market 2020 Global Analysis, Size, Share, Trends, Opportunities and Growth 2026”

PUNE, MAHARASTRA, INDIA, November 30, 2020 /EINPresswire.com/ —

Digital Therapeutics Market 2020

Global Digital Therapeutics Scope and Market Size

The global Digital Therapeutics market has some exclusive products listed under its name that are highly in demand across the major industries of the globe. Some of the common industries who are putting in many efforts to get these products implemented into their business operations include automobile, healthcare, software and others. People across the globe now understand the real efficacy of the products listed under the global Digital Therapeutics market for running seamless and productive business operations. The market is thriving at a larger scale with the help of key players. The key players are contributing their collective efforts to meet the diverse needs and requirements of the consumers across the globe.

Major Market Players in Digital Therapeutics Business

The products manufactured by the key players under the global Digital Therapeutics market are technologically advanced and are meant for serving the designated purposes. The range of applications that can be integrated by using these products is endless. Therefore, industries are willing to implement it into their business operations to see if the productivity rates can go high. As the demand is increasing, the stocks need to go up as well. Therefore, the key players have upgraded their production infrastructure to ensure that the manufacturing pace can be increased to meet the rising demand requests. The supply and demand chain is managed by the key players to ensure that the market runs seamlessly.

The top players covered in Digital Therapeutics Market are:

Proteus Digital Health
Omada Health
WellDoc
2Morrow
Livongo Health
Propeller Health
Twine Health
Canary Health

Get Sample Copy of the Report @ https://www.wiseguyreports.com/sample-request/5049172-global-digital-therapeutics-market-size-status-and-forecast-2020-2026

Digital Therapeutics Market Segmental Analysis

The report forecasts on the growth potential of the global Digital Therapeutics market. Along with that, the report also puts focus on the market segmentation that is categorized on different aspects such as applications, end-users, product types, the technology used and others. It also highlights the regional classification that explains the local strength of the global Digital Therapeutics market across various parts of the world. Keeping all the positive factors in mind, there is a prediction that the market size of the global Digital Therapeutics industry in the current forecast period 2021 to 2026 will be high. This predicted revenue figure is higher as compared to the market size of the previous forecast period. It is so because the demands are exponentially high in the present period.

Market segment by Type, the product can be split into

Software
Devices

Market segment by Application, split into

Diabetes
Obesity
Cardio Vascular Diseases (CVD)
Central Nervous System (CNS) Disease
Gastrointestinal Disorders (GID)
Respiratory Diseases
Smoking Cessation
Others

Regional Analysis of Digital Therapeutics Market

The global Digital Therapeutics market is widely spread across various regions of the globe. All the areas have recorded higher market growth in the past few years. These countries have reported increased sales in the past forecast period. As the demands are high, the revenue generated at the end of the year, 2019 will be recorded higher as compared to the previous forecast period. The key players have a significant role to play in it.

For Customisation and Query @ https://www.wiseguyreports.com/enquiry/5049172-global-digital-therapeutics-market-size-status-and-forecast-2020-2026

Table of Contents –Analysis of Key Points

1 Industry Overview of Digital Therapeutics

2 Global Growth Trends by Regions
2.1 Digital Therapeutics Market Perspective (2015-2026)
2.2 Digital Therapeutics Growth Trends by Regions
2.2.1 Digital Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Digital Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Digital Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Digital Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Digital Therapeutics Players (Opinion Leaders)
……

13 Company Profiles and Key Figures in Digital Therapeutics Business

13.1 Proteus Digital Health
13.1.1 Proteus Digital Health Company Details
13.1.2 Proteus Digital Health Business Overview and Its Total Revenue
13.1.3 Proteus Digital Health Digital Therapeutics Introduction
13.1.4 Proteus Digital Health Revenue in Digital Therapeutics Business (2015-2020))
13.1.5 Proteus Digital Health Recent Development
13.2 Omada Health
13.2.1 Omada Health Company Details
13.2.2 Omada Health Business Overview and Its Total Revenue
13.2.3 Omada Health Digital Therapeutics Introduction
13.2.4 Omada Health Revenue in Digital Therapeutics Business (2015-2020)
13.2.5 Omada Health Recent Development
13.3 WellDoc
13.3.1 WellDoc Company Details
13.3.2 WellDoc Business Overview and Its Total Revenue
13.3.3 WellDoc Digital Therapeutics Introduction
13.3.4 WellDoc Revenue in Digital Therapeutics Business (2015-2020)
13.3.5 WellDoc Recent Development
13.4 2Morrow
13.4.1 2Morrow Company Details
13.4.2 2Morrow Business Overview and Its Total Revenue
13.4.3 2Morrow Digital Therapeutics Introduction
13.4.4 2Morrow Revenue in Digital Therapeutics Business (2015-2020)
13.4.5 2Morrow Recent Development
13.5 Livongo Health
13.5.1 Livongo Health Company Details
13.5.2 Livongo Health Business Overview and Its Total Revenue
13.5.3 Livongo Health Digital Therapeutics Introduction
13.5.4 Livongo Health Revenue in Digital Therapeutics Business (2015-2020)
13.5.5 Livongo Health Recent Development
Continued…..

NORAH TRENT
Wise Guy Reports
+162 825 80070
email us here


Source: EIN Presswire